Loading...
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE‐1407)
LESSONS LEARNED: Palbociclib demonstrated no detectable activity in molecularly unselected and heavily pretreated patients with advanced grade 1/2 pancreatic neuroendocrine tumors. Predictive biomarkers that improve patient selection should be investigated in future studies of palbociclib. BACKGROUN...
Na minha lista:
| Udgivet i: | Oncologist |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley & Sons, Inc.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7485337/ https://ncbi.nlm.nih.gov/pubmed/32045050 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0033 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|